We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

83 hedge funds and large institutions have $107M invested in OncoMed Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more call options, than puts

Call options by funds: $2.25M | Put options by funds: $1.05M

70% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 20

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

0% more funds holding

Funds holding: 83 → 83 (0)

57% less capital invested

Capital invested by funds: $247M → $107M (-$140M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
83
Holders Change
–
Holders Change %
0%
% of All Funds
2.21%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.03%
New
11
Increased
34
Reduced
20
Closed
10
Calls
$2.25M
Puts
$1.05M
Net Calls
+$1.21M
Net Calls Change
+$174K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$4.08M
2
First Eagle Investment Management
First Eagle Investment Management
New York
+$2.17M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$1.95M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.94M
5
BIM
Bogle Investment Management
Massachusetts
+$1.31M

Top Sellers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
-$5.37M
2
Wells Fargo
Wells Fargo
California
-$4.5M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$3.96M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.94M
5
Morgan Stanley
Morgan Stanley
New York
-$1.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
NSEDCP
26
NJ State Employees Deferred Compensation Plan
New Jersey
$784K – – –
BC
27
Birchview Capital
Vermont
$715K +$141K +12,000 +20%
QI
28
QS Investors
New York
$650K – – –
BIM
29
BlackRock Investment Management
Delaware
$598K +$117 +10 +0%
Goldman Sachs
30
Goldman Sachs
New York
$572K +$496K +42,274 +295%
HCM
31
Hodges Capital Management
Texas
$556K +$235K +20,000 +57%
TCIM
32
TIAA CREF Investment Management
New York
$542K -$432K -36,836 -41%
Millennium Management
33
Millennium Management
New York
$479K +$556K +47,356 New
JP Morgan Chase
34
JP Morgan Chase
New York
$447K -$1.11M -94,936 -68%
Charles Schwab
35
Charles Schwab
California
$427K +$8.38K +714 +2%
Deutsche Bank
36
Deutsche Bank
Germany
$406K +$118K +10,089 +33%
PI
37
Putnam Investments
Massachusetts
$388K +$2.87K +244 +0.6%
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$362K +$51.9K +4,418 +14%
AA
39
ALPS Advisors
Colorado
$342K -$68.1K -5,802 -15%
NFA
40
Nationwide Fund Advisors
Ohio
$339K -$13.1K -1,115 -3%
TAM
41
Tocqueville Asset Management
New York
$315K -$306K -26,050 -46%
GT
42
Glenmede Trust
Pennsylvania
$290K – – –
TA
43
Teachers Advisors
New York
$278K +$37.2K +3,165 +13%
Handelsbanken Fonder
44
Handelsbanken Fonder
Sweden
$253K +$294K +25,000 New
PP
45
PDT Partners
New York
$250K +$94.5K +8,050 +48%
TC
46
TFS Capital
Pennsylvania
$250K +$290K +24,726 New
ProShare Advisors
47
ProShare Advisors
Maryland
$246K -$27.2K -2,320 -9%
PCM
48
Piermont Capital Management
Missouri
$221K +$9.8K +835 +4%
Morgan Stanley
49
Morgan Stanley
New York
$214K -$1.52M -129,122 -86%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$178K – – –
1
2
3 4

OMED Hedge Fund Activity: Q1 2016 in Review

83 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q1 2016, worth a combined $107M — down 57% from $247M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new OMED positions and 10 closed out — a net gain of 1 holder — while 34 added to existing stakes and 20 trimmed.

The largest buyer was BVF Inc, adding an estimated $4.08M. The largest seller was Visium Asset Management, exiting entirely with an estimated $5.37M sold.

  • 83 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $107M of OncoMed Pharmaceuticals, Inc. stock for Q1 2016, down 57% quarter-over-quarter.
  • 11 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q1 2016 and 10 closed out, a net change of +1 holder.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q1 2016 was BVF Inc, an estimated $4.08M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q1 2016 was Visium Asset Management, an estimated $5.37M sold.

Based on aggregated 13F filings for Q1 2016.